Bausch Health Companies Inc. 8-K

What Happened

• Bausch Health Companies Inc. (BHC) filed a Form 8‑K on January 23, 2026 (Item 7.01) disclosing a press release that announces the results of the global Phase 3 RED‑C clinical program. The program evaluated an amorphous‑rifaximin solid soluble dispersion in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy. The press release is furnished as Exhibit 99.1 and is incorporated by reference into the 8‑K.

Key Details

• Filing date: January 23, 2026 (Form 8‑K, Item 7.01 — Regulation FD Disclosure).
• Program: Global Phase 3 RED‑C clinical program.
• Candidate: Amorphous‑rifaximin solid soluble dispersion.
• Indication studied: Primary prevention of hepatic encephalopathy in adults with liver cirrhosis.
• Press release attached to the 8‑K as Exhibit 99.1.

Why It Matters

• Phase 3 results are a key milestone for a drug’s regulatory and commercial prospects; investors should read the attached press release for efficacy, safety, and next‑step details. The 8‑K is a Regulation FD disclosure, meaning the company is publicly communicating potentially material clinical results to all investors at once. Monitor Bausch Health for follow‑up SEC filings and company statements that provide data, regulatory plans, or timelines.